Medical and Dental Consultantsí Association of Nigeria
Home - About us - Editorial board - Search - Ahead of print - Current issue - Archives - Submit article - Instructions - Subscribe - Advertise - Contacts - Login 
  Users Online: 1240   Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
 
ORIGINAL ARTICLE
Year : 2018  |  Volume : 21  |  Issue : 6  |  Page : 735-742

A 3-year study of deferasirox therapy in sickle cell disease patients in Basra, Southern Iraq


1 Center for Hereditary Blood Diseases, Basra Maternity and Children Hospital, Basra, Iraq
2 Center for Hereditary Blood Diseases, Basra Maternity and Children Hospital; Department of Pediatrics, College of Medicine, University of Basra, Basra, Iraq

Correspondence Address:
Dr. M K Hassan
Department of Pediatrics, College of Medicine, University of Basra, Basra
Iraq
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/njcp.njcp_162_17

Rights and Permissions

Background: Patients with sickle cell disease (SCD) may require repeated transfusions, which inevitably lead to iron overload (IOL). Aims: This study aims to assess the effectiveness and safety of oral deferasirox (DFX) in patients with SCD and transfusional IOL. Patients and Methods: A descriptive study has been performed on patients with SCD who have completed at least 3 years on DFX. Height and weight were checked every 3–6 months. The efficacy was assessed based on serum ferritin (SF) levels. The safety was assessed based on adverse events (AEs), alanine aminotransferase (ALT), and serum creatinine (S. Cr) levels. Results: A total of 102 patients (61 males and 41 females) were recruited. Their mean daily iron intake was 0.13 ± 0.06 mg/kg. SF levels declined significantly from 2434.1 ± 132.9 ng/ml at the start of the study to 1655.8 ± 154.2 ng/ml at the end of the study (P < 0.05), with significant decreases observed after increasing the DFX dose to ≥ 30 mg/kg/day. ALT (12.8 ± 9.9 vs. 12.1 ± 7.1 U/L) and S. Cr (72.4 ± 9.2 vs. 74.1 ± 7.9 mmol/L) levels did not show significant differences from the start to the end of the study (P > 0.05). Thirty-eight patients (37%) developed AEs. The most common were abdominal pain (24.5%), diarrhea (8.0%), and nausea (7.8%). AEs were predominantly transient and mild to moderate in nature. Conclusions: This study has revealed that DFX is a safe, tolerable, and effective drug for reducing IOL in SCD patients, though it is associated with mild and transient adverse events.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed895    
    Printed32    
    Emailed0    
    PDF Downloaded117    
    Comments [Add]    

Recommend this journal